Virtual High Throughput Screening (HTS) with AI
Increase performance and decrease the cost of high throughput screening with Artificial Intelligence (AI)
The traditional drug discovery process is a high-risk, high-return approach that is costly and time-consuming.
For that reason, Artificial Intelligence has been attracting attention in this field as an innovative technology that can increase the possibility of success, while dramatically reducing costs and time for research and development.
Why AI is spreading to drug discovery
New drug discovery is a field that requires vast resources, is time-intensive, and requires an integration of a wide variety of specialized skills in each step of the process. It is estimated that 1 in 10 small molecules projects become candidates for clinical trials, and only about 1 in 10 of those compounds will then pass successfully through clinical trials. Our virtual HTS solution transforms the drug development process, by speeding up hit discovery, from weeks to hours.
Our experience in drug discovery
Our journey in the biomedical sector started by developing an AI solution (in collaboration with Universite Libre de Bruxelles) that can predict an episode of Atrial Fibrillation before it occurs. We achieved a world-first in predicting this pathology. We then realized that some of our expertise and work could be used in the field of drug discovery.
We developed our own state-of-the-art solution for drug discovery. This early-stage technology is highly effective for virtual high-throughput screening (vHTS). The technology has provided performances superior to common virtual screening tools and methods, thanks to our novel algorithm that keeps on improving every day.
Discovering new and successful drugs is a hard and time-consuming process. Our virtual HTS solution can improve drug development by:
identifying more promising drug candidates;
raising the “hit rate” or the percentage of drug candidates that make it through clinical trials and gain regulatory approval;
speeding up the overall process;
focusing HTS efforts on promising compounds and bioassays.
reducing time and costs (expensive reagents, expensive bioassays).
Our virtual HTS solution can help companies make their search for new pharmaceuticals quicker, cheaper, and more effective.
AI can save 40%-50% of the time in compound creation and screening, saving up to $26 million in screening costs per year. Our solution has the capacity to process and analyze extremely large libraries in a fraction of time and money, hence increasing the speed and efficiency of the drug development process, and decreasing the time to market.
The average cost to bring a new drug to the market is estimated at $2.6 billion. Our solution enables biopharma organizations to dedicate their resources to the most promising compounds and save considerable resources.
Our solution enables biopharma organizations to increase their chances to find new promising compounds, or generate new insights on existing compounds.
Let's get in touch!
Leave us your contact details or give us a call and we will propose some slots to have an initial confidential exchange.